Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018)
Canton, R. ; Loza, E. ; Arcay, R.M. ; Cercenado, E. ; Castillo, F.J. (Universidad de Zaragoza) ; Cisterna, R. ; Galvez-Benitez, L. ; González Romo, F. ; Hernandez-Cabezas, A. ; Rodriguez-Lozano, J. ; Suarez-Barrenechea, A.I. ; Tubau, F. ; Diaz-Reganon, J. ; Lopez-Mendoza, D.
Resumen: Objective. To analyse the susceptibility to ceftolozane-tazobactam and comparators in Enterobacterales and Pseudomonas aeruginosa isolates recovered from intraabdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream infection (BSI) in the SMART (Study for Monitoring Antimicrobial Resistance Trends) study. Methods. The susceptibility of 5, 351 isolates collected in 11 Spanish hospitals (2016-2018) were analysed (EUCAST-2020 criteria) by broth microdilution and were phenotypically studied for the presence of extended-spectrum beta-lactamases (ESBL). Ceftolozane-tazobactam and/or carbapenem resistant isolates were genetically characterized for ESBL and carbapenemases. Results. Escherichia coli was the most frequent pathogen (49.3% IAI, 54.9% UTI, 16.7% RTI and 50% BSI), followed by Klebsiella pneumoniae (11.9%, 19.1%, 13.1% and 15.4%, respectively). P. aeruginosa was isolated in 9.3%, 5.6%, 32% and 9%, respectively. The frequency of isolates with ESBLs (2016-2017) was: 30.5% K. pneumoniae, 8.6% E. coli, 2.3% Klebsiella oxytoca and 0.7% Proteus mirabilis. Ceftolozane-tazobactam was very active against non-ESBL-(99.3% susceptible) and ESBL-(95.2%) producing E. coli being less active against K. pneumoniae (98% and 43.1%, respectively) isolates. CTX-M-15 was the most prevalent ESBL in E. coli (27.5%) and K. pneumoniae (51.9%) frequently associated with OXA-48-like carbapenemase. Overall, 93% of P. aeruginosa isolates were susceptible to ceftolozane-tazobactam, preserving this activity (>75%) in isolates resistant to other beta-lactams except in those resistant to meropenen or ceftazidime-avibactam. GES-5, PER-1, VIM-1/2 were the most prevalent enzymes in isolates resistant to ceftolozane-tazobactam. Conclusions. Ceftolozane-tazobactam showed high activity rates against isolates recovered in the SMART study although it was affected in K. pneumoniae and P. aeruginosa isolates with ESBL and/or carbapenemases.
Idioma: Inglés
DOI: 10.37201/req/019.2021
Año: 2021
Publicado en: Revista española de quimioterapia 34, 3 (2021), 228-237
ISSN: 0214-3429
Factor impacto JCR: 2.515 (2021)
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 206 / 279 = 0.738 (2021) - Q3 - T3
Categ. JCR: MICROBIOLOGY rank: 116 / 138 = 0.841 (2021) - Q4 - T3
Factor impacto CITESCORE: 2.3 - Pharmacology, Toxicology and Pharmaceutics (Q3) - Medicine (Q3)
Factor impacto SCIMAGO: 0.44 - Microbiology (medical) (Q3) - Medicine (miscellaneous) (Q3)
Tipo y forma: Article (Published version)
Área (Departamento): Área Microbiología (Dpto. Microb.Ped.Radio.Sal.Pú.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes.
Exportado de SIDERAL (2023-05-18-15:27:25)
Visitas y descargas
Idioma: Inglés
DOI: 10.37201/req/019.2021
Año: 2021
Publicado en: Revista española de quimioterapia 34, 3 (2021), 228-237
ISSN: 0214-3429
Factor impacto JCR: 2.515 (2021)
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 206 / 279 = 0.738 (2021) - Q3 - T3
Categ. JCR: MICROBIOLOGY rank: 116 / 138 = 0.841 (2021) - Q4 - T3
Factor impacto CITESCORE: 2.3 - Pharmacology, Toxicology and Pharmaceutics (Q3) - Medicine (Q3)
Factor impacto SCIMAGO: 0.44 - Microbiology (medical) (Q3) - Medicine (miscellaneous) (Q3)
Tipo y forma: Article (Published version)
Área (Departamento): Área Microbiología (Dpto. Microb.Ped.Radio.Sal.Pú.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. Exportado de SIDERAL (2023-05-18-15:27:25)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Articles
Record created 2022-03-22, last modified 2023-05-19